Haifeng Xu

Haifeng Xu

Auto-generated profile, based on publicly available information

Haifeng Xu

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YYYanping Yin
Yanping Yin
PAPaschalis Athanasiadis
Paschalis Athanasiadis
LKLinda Karlsen
Linda Karlsen
AUAleksandra Urban
Aleksandra Urban
HXHaifeng Xu
Haifeng Xu
SSSigrid S. Skånland
Sigrid S. Skånland
Purpose: PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). Although patients may show an initial response to these therapies, development of treatment intolerance or resistance remain clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of 10 PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki. Experimental Design: Peripheral blood mononuclear cell samples (n = 51 in total) from treatment-naïve and PI3Ki-treated patients with CLL were studied. Cells were profiled against 10 PI3Ki and the Bcl-2 antagonist venetoclax. Cell signaling and immune phenotypes were analyzed by flow cytometry. Cell viability was monitored by detection of cleaved caspase-3 and the CellTiter-Glo assay. Results: pan-PI3Kis were most effective at inhibiting PI3K signaling and cell viability, and showed activity in CLL cells from both treatment-naïve and idelalisib-refractory/intolerant patients. CLL cells from idelalisib-refractory/intolerant patients showed overall reduced protein phosphorylation levels. The pan-PI3Ki copanlisib, but not the p110δ inhibitor idelalisib, inhibited PI3K signaling in CD4+ and CD8+ T cells in addition to CD19+ B cells, but did not significantly affect T-cell numbers. Combination treatment with a PI3Ki and venetoclax resulted in synergistic induction of apoptosis. Analysis of drug sensitivities to 73 drug combinations and profiling of 31 proteins stratified responders to idelalisib and umbralisib, respectively. Conclusions: Our findings suggest novel treatment vulnerabilities in idelalisib-refractory/intolerant CLL, and indicate that ex vivo functional profiling may stratify PI3Ki responders.

14 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
YYYanping Yin
Yanping Yin
HXHaifeng Xu
Haifeng Xu
LHLiye He
Liye He
JBJennifer R. Brown
Jennifer R. Brown
AMAnthony Mato
Anthony Mato
SSSigrid S. Skånland
Sigrid S. Skånland
Purpose: The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select the best therapy, predictive biomarkers are necessary. In this study, we used the phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as a model to (i) understand the impact of targeted treatment on cell signaling and immunophenotypes in responders and nonresponders, (ii) identify molecular features that predict individual treatment responses, and (iii) suggest alternative treatment options for the nonresponders. Experimental Design: We performed functional phenotyping of CLL cells from patients enrolled in two clinical trials with umbralisib, administered either as a monotherapy (NCT02742090, n = 55) or in combination with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (NCT04624633, n = 12). Results: We found that umbralisib monotherapy led to significant changes in (phospho)protein levels, including AKT (pS473), in responders but not in nonresponders. Furthermore, the proportion of cytotoxic natural killer (NK) cells increased at the end of the study but only in responders, suggesting a role in the antitumor response. To identify molecular predictors of response, we used the baseline levels of 30 (phospho)proteins in the monotherapy cohort as input features for a machine learning model, which achieved significant prediction accuracy in cross-validation and maintained its predictive power in the combination cohort. Drug sensitivity profiling of the CLL cells at baseline suggested that PI3K + Bcl-2 inhibitors are effective in umbralisib nonresponders. Conclusions: Functional phenotyping reveals differential cellular responses to umbralisib treatment in responders and nonresponders; predicts treatment response of individual patients with CLL; and suggests alternative treatment options for the nonresponders.

1 April 2023
Verified
Other
Open access
YYYanping Yin
Yanping Yin
PAPaschalis Athanasiadis
Paschalis Athanasiadis
LKLinda Karlsen
Linda Karlsen
AUAleksandra Urban
Aleksandra Urban
HXHaifeng Xu
Haifeng Xu
SSSigrid S. Skånland
Sigrid S. Skånland
Supplementary Figure from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

1 April 2023
Verified
Other
Open access
YYYanping Yin
Yanping Yin
PAPaschalis Athanasiadis
Paschalis Athanasiadis
LKLinda Karlsen
Linda Karlsen
AUAleksandra Urban
Aleksandra Urban
HXHaifeng Xu
Haifeng Xu
SSSigrid S. Skånland
Sigrid S. Skånland
Supplementary Figure from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

1 April 2023
Verified
Other
Open access
YYYanping Yin
Yanping Yin
PAPaschalis Athanasiadis
Paschalis Athanasiadis
LKLinda Karlsen
Linda Karlsen
AUAleksandra Urban
Aleksandra Urban
HXHaifeng Xu
Haifeng Xu
SSSigrid S. Skånland
Sigrid S. Skånland
Supplementary Table from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia